299 related articles for article (PubMed ID: 32141607)
1. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
[TBL] [Abstract][Full Text] [Related]
2. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Zhao FH; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Katki HA; Schiffman M
Ann Intern Med; 2018 Jan; 168(1):20-29. PubMed ID: 29181509
[TBL] [Abstract][Full Text] [Related]
3. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
4. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
[TBL] [Abstract][Full Text] [Related]
5. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
6. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
7. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
[TBL] [Abstract][Full Text] [Related]
8. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
10. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.
Castle PE; Shaber R; LaMere BJ; Kinney W; Fetterma B; Poitras N; Lorey T; Schiffman M; Dunne A; Ostolaza JM; McKinney S; Burk RD
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):946-53. PubMed ID: 21415357
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
13. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
Luyten A; Buttmann-Schweiger N; Luyten K; Mauritz C; Reinecke-Lüthge A; Pietralla M; Meijer CJ; Petry KU
Int J Cancer; 2014 Sep; 135(6):1408-16. PubMed ID: 24519782
[TBL] [Abstract][Full Text] [Related]
14. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.
Gage JC; Katki HA; Schiffman M; Fetterman B; Poitras NE; Lorey T; Cheung LC; Castle PE; Kinney WK
Int J Cancer; 2015 Apr; 136(7):1665-71. PubMed ID: 25136967
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
16. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
17. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
[TBL] [Abstract][Full Text] [Related]
18. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
[TBL] [Abstract][Full Text] [Related]
19. A cohort study of cervical screening using partial HPV typing and cytology triage.
Schiffman M; Hyun N; Raine-Bennett TR; Katki H; Fetterman B; Gage JC; Cheung LC; Befano B; Poitras N; Lorey T; Castle PE; Wentzensen N
Int J Cancer; 2016 Dec; 139(11):2606-15. PubMed ID: 27509172
[TBL] [Abstract][Full Text] [Related]
20. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
